Why did SYFOVRE revenue decline even as injection volumes grew?

SYFOVRE injection volumes rose 17% in 2025, but net revenue fell 4% to $587 million due to worsening gross-to-net dynamics. Copay assistance programs and payer rebates compressed the realized revenue per injection, overwhelming the volume gains.

What competitors threaten SYFOVRE in geographic atrophy?

Iveric Bio's Izervay is already on the market competing for geographic atrophy patients. Regeneron and Alnylam are developing a C5 combination therapy expected by late 2027. Both entrants will further pressure SYFOVRE's market share during the CVR measurement window.

What is the downside risk if the Biogen-Apellis deal falls through?

Without the acquisition floor, Apellis trades on its own fundamentals: negative free cash flow of -$15 million TTM, a declining SYFOVRE franchise, and a forward P/E of -157x. Cantor Fitzgerald's price target of $31 implies roughly 23% downside from the current $40.23 price.

Can Empaveli's nephrology pipeline offset SYFOVRE's decline?

Empaveli's expansion into C3 glomerulopathy addresses an unmet need, but the franchise is early-stage and must carry the entire growth thesis if SYFOVRE continues to erode. Apellis generated only $1.0 billion in TTM revenue across its entire portfolio, leaving limited margin for a slow nephrology ramp.

Apellis SYFOVRE Sales Fall 4% on Rising Volume, Exposing a CVR Worth Zero

Q: What is the Biogen-Apellis CVR and how does it work?

The contingent value right pays Apellis shareholders up to $4 per share if SYFOVRE hits $1.5 billion in annual global net sales between 2027 and 2030, with an additional tier at $2 billion. It is non-transferable, meaning it cannot be traded separately from the stock, which prevents independent price discovery.

NEW YORK, April 1 —

SYFOVRE injection volumes rose 17% in 2025. Revenue fell 4% to $587mn. That divergence tells you everything about what Biogen actually bought — and what the CVR is actually worth.

Signal snapshot

SYFOVRE 2025 revenue: $587mn, down 4% YoY despite 17% injection volume growth
Forward P/E: -157.1x; TTM free cash flow: -$15mn
CVR requires $1.5bn–$2.0bn annual sales (155–240% above current run rate) — JPMorgan's model assumes neither threshold is met

What the Street Believes

The market treats $41/share as a fair-to-generous exit. Biogen's larger salesforce will fix SYFOVRE's commercial execution. The CVR adds optionality on top.

This view prices in zero deterioration from the gross-to-net trend and ignores two competitors arriving before the CVR window closes. The stock at $40.23 reflects near-certainty the base deal closes, with the CVR as a free lottery ticket.

What the Data Shows

The buried signal is the gross-to-net spread. More patients received SYFOVRE injections in 2025 than in 2024. Yet Apellis collected less money per injection — enough to drag total revenue negative YoY.

"Apellis shareholders are eligible to receive up to an additional $4 per share via a non-transferable CVR if SYFOVRE achieves $1.5 billion in annual global net sales in any calendar year between 2027 and 2030, with an additional tier at $2 billion — milestones JPMorgan's model does not assume will be reached."

The math is unforgiving. Reaching $1.5bn from $587mn requires a 155% increase in net sales. That demands either a volume tripling with stable pricing or a massive reversal of copay assistance erosion — neither of which is plausible with Iveric Bio's Izervay already competing and Regeneron/Alnylam's C5 combination expected by late 2027.

The non-transferable structure of the CVR is the quiet tell. Merger arbitrageurs cannot strip and separately trade the CVR. That means no independent price discovery, no liquid market to reflect probability-weighted value. Any residual option value stays trapped inside the arb position, invisible.

Why This Changes the Calculus

If the CVR is worth zero — and JPMorgan's own model assumes exactly that — then the acquisition price is $41 flat. The street models $41–$45 of total consideration. The data shows $41, period.

At $41/share, you are paying roughly 5.6bn for a business generating -$15mn in TTM free cash flow. The entire growth thesis rests on Empaveli's expansion into C3 glomerulopathy and other nephrology indications, a franchise that must carry the weight of a declining flagship product.

The metric to watch is Q1 2026 SYFOVRE net revenue per injection. If the gross-to-net spread widens further, even $41 looks rich. Every quarter of continued pricing erosion makes the Empaveli bet more binary.

The Counterargument

Biogen's infrastructure could genuinely improve SYFOVRE's commercial trajectory. A larger salesforce, better payer negotiations, and international expansion could stabilize or reverse the gross-to-net trend. Empaveli's nephrology pipeline, particularly in C3 glomerulopathy, addresses a genuine unmet need with limited competition.

The earnings trajectory shows improvement: Q2 2025 delivered $1.67 EPS versus $0.94 consensus, a 77.5% beat. That suggests operational leverage exists when volume converts to revenue.

But one strong quarter does not erase structural pricing decay. The 17%-volume-up, 4%-revenue-down divergence is not a timing issue. It reflects payer dynamics that a bigger salesforce cannot fix. Biogen would need to restructure SYFOVRE's entire copay architecture — mid-launch, mid-competition — to bend this curve.

Verdict

The real acquisition price is not the headline $45. When Biogen announced the $5.6 billion deal, the CVR looked like meaningful upside. The gross-to-net data says otherwise. At $41, you own a cash-flow-negative ophthalmology franchise facing two new competitors, plus an early-stage nephrology pipeline that needs to work perfectly to justify the price. The CVR is a rounding error dressed as optionality.